San Diego, California-based NuVasive, Inc. has announced the commercial launch of Modulus TLIF-A, a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion (TLIF) procedure. This completes the NuVasive’s Advanced Materials Science (AMS) portfolio for all major posterior interbody fusion techniques used in TLIF.
NuVasive Launches Porous Titanium TLIF Implants
1 min read Premium comments
#nuvasiveSecondary#tlif#surfacetopography
“The Modulus TLIF-A system is the perfect synergy between optimized material properties and deliverability,” said Jeffrey L. Gum, M.D., orthopedic surgeon at the Norton Leatherman Spine Center. “The lattice design allows for improved imaging characteristics, a prime environment to promote fusion and an ideal modulus of elasticity. Additionally, the system optimizes surgical workflow by utilizing a single instrument for implant insertion and articulation.”
According to the company, “Modulus TLIF-A is an anteriorly placed implant featuring a porous titanium surface technology that is designed to promote bone in-growth and bone on-growth. Animal studies also demonstrated stronger osseointegration than solid implants with smooth or rough surfaces. This optimized lattice structure enables enhanced imaging for visualization of spinal fusion compared to solid titanium interbody implants.”
Matt Link told OTW, “When designing the Modulus TLIF-A system, the surgeon team and engineers strived to incorporate top of the line Advanced Material Science technology with true surgical efficiency for a procedure that provides support to the anterior column of the spine and aids in alignment restoration objectives. Patient outcomes, procedural versatility and user centered design were top considerations when bringing this best-in-class technology into the hands of surgeons.”
“Surface topography, specifically porosity, matters when it comes to selecting an implant that will contribute to positive patient outcomes. NuVasive’s application of truly porous endplates to its implant portfolio is rooted behind the technology’s proven evidence to elicit a strong osteogenic cellular response and promotion of osseointegration, transforming the way patients recover from spine surgery.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.